Michael D Stein1,2, Micah T Conti1, Debra S Herman1,3, Bradley J Anderson1, Genie L Bailey3,4, Donnell Van Noppen1, Ana M Abrantes1,3. 1. Department of Behavioral Medicine and Addictions Resaerch, Butler Hospital, Providence, Rhode Island. 2. Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts. 3. Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, Rhode Island. 4. Stanley Street Treatment and Resources, Inc, Fall River, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: Despite the benefits of maintenance buprenorphine treatment for opioid use disorder (OUD), many individuals report an interest in discontinuing the medication, while also expressing worries about tapering. The purpose of this study was to develop a measure of worries about buprenorphine discontinuation ("Off Bupe") and determine the demographic and clinical characteristics associated with these worries. METHODS: Between May 2017 and May 2018, we surveyed adults in an outpatient primary care buprenorphine program (n = 138). Reliability and validity of the Off Bupe measure were examined. RESULTS: Participants averaged 39 years of age, 54% were male, average duration of buprenorphine was 189 weeks and 85.5% reported eventually wanting to discontinue buprenorphine, although fewer than 10% were actively tapering. We derived two scales, withdrawal symptom worry (10 items, ɑ = 0.94) and relapse worry (7 items, ɑ = 0.88). Worry about symptoms was positively associated with current buprenorphine dose (P = 0.016), physical discomfort avoidance (P < 0.001), and inversely associated with self-efficacy to quit buprenorphine (P < 0.001) and distress tolerance (P < 0.001). Worry about opioid relapse was associated positively with age (P = 0.019), current buprenorphine dose (P = 0.004), physical discomfort avoidance (P < 0.001), and impulsivity (P = 0.002), and inversely associated with self-efficacy to quit buprenorphine (P < 0.001). DISCUSSION AND CONCLUSIONS: Psychometric evaluation of the "Off Bupe" scale demonstrated its content and construct validity and internal reliability. SCIENTIFIC SIGNIFICANCE: The scale might help individuals with OUD and their providers identify concerns about discontinuing buprenorphine. (Am J Addict 2019;28:270-276).
BACKGROUND AND OBJECTIVES: Despite the benefits of maintenance buprenorphine treatment for opioid use disorder (OUD), many individuals report an interest in discontinuing the medication, while also expressing worries about tapering. The purpose of this study was to develop a measure of worries about buprenorphine discontinuation ("Off Bupe") and determine the demographic and clinical characteristics associated with these worries. METHODS: Between May 2017 and May 2018, we surveyed adults in an outpatient primary care buprenorphine program (n = 138). Reliability and validity of the Off Bupe measure were examined. RESULTS:Participants averaged 39 years of age, 54% were male, average duration of buprenorphine was 189 weeks and 85.5% reported eventually wanting to discontinue buprenorphine, although fewer than 10% were actively tapering. We derived two scales, withdrawal symptom worry (10 items, ɑ = 0.94) and relapse worry (7 items, ɑ = 0.88). Worry about symptoms was positively associated with current buprenorphine dose (P = 0.016), physical discomfort avoidance (P < 0.001), and inversely associated with self-efficacy to quit buprenorphine (P < 0.001) and distress tolerance (P < 0.001). Worry about opioid relapse was associated positively with age (P = 0.019), current buprenorphine dose (P = 0.004), physical discomfort avoidance (P < 0.001), and impulsivity (P = 0.002), and inversely associated with self-efficacy to quit buprenorphine (P < 0.001). DISCUSSION AND CONCLUSIONS: Psychometric evaluation of the "Off Bupe" scale demonstrated its content and construct validity and internal reliability. SCIENTIFIC SIGNIFICANCE: The scale might help individuals with OUD and their providers identify concerns about discontinuing buprenorphine. (Am J Addict 2019;28:270-276).
Authors: Louisa Degenhardt; Harvey A Whiteford; Alize J Ferrari; Amanda J Baxter; Fiona J Charlson; Wayne D Hall; Greg Freedman; Roy Burstein; Nicole Johns; Rebecca E Engell; Abraham Flaxman; Christopher J L Murray; Theo Vos Journal: Lancet Date: 2013-08-29 Impact factor: 79.321
Authors: Roger D Weiss; Jennifer Sharpe Potter; Margaret L Griffin; Scott E Provost; Garrett M Fitzmaurice; Katherine A McDermott; Emily N Srisarajivakul; Dorian R Dodd; Jessica A Dreifuss; R Kathryn McHugh; Kathleen M Carroll Journal: Drug Alcohol Depend Date: 2015-03-06 Impact factor: 4.492
Authors: Alexander M Ponizovsky; Anatoly Margolis; Ludmila Heled; Paula Rosca; Irena Radomislensky; Alexander Grinshpoon Journal: Subst Use Misuse Date: 2010 Impact factor: 2.164
Authors: Caroline B Pantazis; Luis A Gonzalez; Brendan J Tunstall; Stephanie A Carmack; George F Koob; Leandro F Vendruscolo Journal: Sci Adv Date: 2021-04-07 Impact factor: 14.136
Authors: Paolo Mannelli; Antoine B Douaihy; Sarah C Akerman; Anna Legedza; James Fratantonio; Abigail Zavod; Maria A Sullivan Journal: Am J Addict Date: 2022-02-09
Authors: Sandra D Comer; Paolo Mannelli; Danesh Alam; Antoine Douaihy; Narinder Nangia; Sarah C Akerman; Abigail Zavod; Bernard L Silverman; Maria A Sullivan Journal: Am J Addict Date: 2020-04-04